NYSEArca - Delayed Quote USD
State Street Consumer Discretionary Select Sector SPDR ETF (XLY)
115.38 -0.82 (-0.71%)
At close: October 30 at 4:00:00 PM EDT
115.50 +0.12 (+0.10%)
After hours: October 30 at 7:13:31 PM EDT
Trade XLY on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for XLY
- Previous Close
116.20 - Open
114.89 - Bid 115.36 x 140000
- Ask 117.00 x 50000
- Day's Range
114.47 - 115.83 - 52 Week Range
105.19 - 125.01 - Volume
10,075,823 - Avg. Volume
6,390,367 - Net Assets 21.27B
- NAV 115.38
- PE Ratio (TTM) 25.45
- Yield 0.86%
- YTD Daily Total Return -2.78%
- Beta (5Y Monthly) 1.18
- Expense Ratio (net) 0.08%
Performance Overview
View MoreTrailing returns as of 10/31/2026. Category is Consumer Cyclical.
People Also Watch
XLP State Street Consumer Staples Select Sector SPDR ETF
89.42 +1.41%
XLI State Street Industrial Select Sector SPDR ETF
167.40 -1.60%
XLB State Street Materials Select Sector SPDR ETF
52.74 +0.40%
XLV State Street Health Care Select Sector SPDR ETF
184.87 +0.45%
XLU State Street Utilities Select Sector SPDR ETF
43.43 +0.67%
Recent News
View More
Research Reports
View MoreBiogen Earnings: Apellis Products Boost Growth Ahead of Key Lupus Readout
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Raising rating to BUY
Biogen Inc. is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases. The company is the market leader in MS drugs and launched the first approved treatments for SMA and AD. The company also sells products that treat plaque psoriasis, non-Hodgkin's lymphoma, lymphocytic leukemia, and rheumatoid arthritis. Current research continues on MS and has expanded to include neuroimmunology, ophthalmology, lupus, and other neuromuscular and movement disorders. Founded in 1978, the company is located in Cambridge, Massachusetts; employs 7,500 people; and is a component of the S&P 500.
Maintaining HOLD on margin and earnings declines
Biogen is a biotech company that develops, manufactures, and sells therapies for treating neurological and neurodegenerative diseases. The company is the market leader in MS drugs and launched the first approved treatments for spinal muscular atrophy and AD. The company also sells products that treat plaque psoriasis, non-Hodgkin's lymphoma, lymphocytic leukemia, and rheumatoid arthritis. Current research continues on MS and has expanded to include neuroimmunology, ophthalmology, lupus, and other neuromuscular and movement disorders. Founded in 1978, the company is located in Cambridge, Massachusetts; employs 7,500 people; and is a component of the S&P 500.
The major stock indices are lower at midday. Wall Street continues to monitor
The major stock indices are lower at midday. Wall Street continues to monitor the price of oil as tensions escalate in the Middle East; the possibility of an interest-rate increase from the Fed; and the ongoing trade dispute with Canada. Crude oil is up another 4% at $97 per barrel and the yield on the 10-year note is at 4.85%.